Herpes zoster virus vaccine (Zostavax) for the prevention of shingles

American Family Physician

Volumn 75, Issue 12, 2007, Pages 1843-1846

  Deyoung, G Robert ^a   Baty, Philip J ^b  

^a Saint Mary's Health Care   (United States)

^b Advantage Health Physicians and Grand Rapids Family Medicine Residency   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNIZATION; MORBIDITY; MORTALITY; PREVENTION AND CONTROL; REVIEW; UNITED STATES; VACCINATION; VARICELLA ZOSTER VIRUS;

EID: 34250738977     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Zostavax (zoster vaccine live) [Product information]. Whitehouse Station, N.J.: Merck & Co., Inc, 2006. Accessed March 5, 2007, at: http://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi.pdf.
2. Advisory Committee on Immunization Practices. ACIP provisional recommendations for the use of zoster vaccine. Accessed March 5, 2007, at: http://www.cdc.gov/nip/recs/provisional_recs/zoster-11-20-06.pdf.
3. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al., for the Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.
4. Gilden DH. Varicella-zoster virus vaccine-grown-ups need it, too. N Engl J Med 2005;352:2344-6.
5. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006;145:317-25.